View in EDS HTML Full Text PDF Full Text

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Saved in:
Bibliographic Details
Title: Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
Authors: Wobser M; Department of Dermatology, University Hospital Wuerzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany., Rosenwald A; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, University Wuerzburg, Germany., Eisele F; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany., Maurus K; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, University Wuerzburg, Germany., Topp M; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany., Duell J; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2026 Aug; Vol. 67 (9), pp. 1990-1993. Date of Electronic Publication: 2026 May 22.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42169664
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Wobser+M%22">Wobser M</searchLink>; Department of Dermatology, University Hospital Wuerzburg, Germany.; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Rosenwald+A%22">Rosenwald A</searchLink>; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, University Wuerzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Eisele+F%22">Eisele F</searchLink>; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Maurus+K%22">Maurus K</searchLink>; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Institute of Pathology, University Wuerzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Topp+M%22">Topp M</searchLink>; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Duell+J%22">Duell J</searchLink>; Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany.; Department of Internal Medicine, Hematology/Oncology, University Hospital Wuerzburg, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2026 Aug; Vol. 67 (9), pp. 1990-1993. <i>Date of Electronic Publication: </i>2026 May 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42169664
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2026.2672106
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1990
    Titles:
      – TitleFull: Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Wobser M
      – PersonEntity:
          Name:
            NameFull: Rosenwald A
      – PersonEntity:
          Name:
            NameFull: Eisele F
      – PersonEntity:
          Name:
            NameFull: Maurus K
      – PersonEntity:
          Name:
            NameFull: Topp M
      – PersonEntity:
          Name:
            NameFull: Duell J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 08
              Text: 2026 Aug
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 67
            – Type: issue
              Value: 9
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1